SARS-CoV-2 and the safety margins of cell-based biological medicinal
products
- Jens Modrof
, - Astrid Kerschbaum,
- Maria Farcet,
- Daniela Niemeyer,
- Victor Corman,
- Thomas Kreil
Jens Modrof
Takeda Pharmaceutical Co Ltd
Corresponding Author:jens.modrof@takeda.com
Author ProfileAbstract
With the pandemic emergence of SARS-CoV-2, the exposure of cell
substrates used for manufacturing of medicines has become a possibility.
Cell lines used in biomanufacturing were thus evaluated for their
SARS-CoV-2 susceptibility, and the detection of SARS-CoV-2 in culture
supernatants was tested by routine adventitious virus testing of
fermenter harvest.02 Jun 2020Submitted to Biotechnology and Bioengineering 03 Jun 2020Submission Checks Completed
03 Jun 2020Assigned to Editor
15 Jun 2020Review(s) Completed, Editorial Evaluation Pending
